Y
Yves Pommier
Researcher at National Institutes of Health
Publications - 847
Citations - 65543
Yves Pommier is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Topoisomerase & DNA. The author has an hindex of 123, co-authored 789 publications receiving 58898 citations. Previous affiliations of Yves Pommier include Purdue University & Kyushu University.
Papers
More filters
Journal ArticleDOI
Authentic HIV-1 integrase inhibitors.
TL;DR: A number of patented HIV-1 IN inhibitors, especially those that possess high selectivity for the strand transfer reaction, are reviewed, particularly those that have a polar coplanar moiety.
Journal ArticleDOI
Mammalian DNA topoisomerase I activity and poisoning by camptothecin are inhibited by simian virus 40 large T antigen.
TL;DR: Rec recombinant large T antigen (T-Ag), a virus encoded helicase with strong affinity for tumor suppressors and cell cycle- and replication-related proteins, suppresses top1 cleavage complexes and top1 catalytic activity and suggests the importance of top1-protein interactions for the regulation of DNA replication and modulation of camptothecin activity.
Journal ArticleDOI
MK-0536 inhibits HIV-1 integrases resistant to raltegravir
Mathieu Métifiot,Barry C. Johnson,Steven J. Smith,Xue Zhi Zhao,Christophe Marchand,Terrence R. Burke,Stephen H. Hughes,Yves Pommier +7 more
TL;DR: It is demonstrated that, like RAL, MK-0536 is highly potent against recombinant IN and viral replication and also effective against INs that carry the three main RAL resistance mutations and against the G118R mutant.
Journal Article
Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
TL;DR: The overall repair capacity estimated by the ability of cells to reactivate UV-damaged pSV-CAT plasmid was increased in MCF-7/C4 cells, suggesting that enhanced DNA repair is one of the factors involved in CPT resistance.
Journal ArticleDOI
Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.
TL;DR: 2-position-modified indenoisoquinolines modified at the 2-position with three-carbon side chains ending with amino substituents are described as dual Top1–TDP1 inhibitors using a structure-based drug design approach.